Research on cartilage regeneration has developed novel sources for human chondrocytes and new regenerative therapies, but appropriate animal models for translational research are needed. Although rabbit models are frequently used in such studies, the availability of immunocompromised rabbits is limited. Here, we investigated the usefulness of an immunosuppressed rabbit model to evaluate directly the efficacy of human chondrocyte sheets through xenogeneic transplantation. Human chondrocyte sheets were transplanted into knee osteochondral defects in Japanese white rabbits administered with immunosuppressant tacrolimus at a dosage of 0.8 or 1.6 mg/kg/day for 4 weeks. Histological evaluation at 4 weeks after transplantation in rabbits administered 1.6 mg/kg/day showed successful engraftment of human chondrocytes and cartilage regeneration involving a mixture of hyaline cartilage and fibrocartilage. No human chondrocytes were detected in rabbits administered 0.8 mg/kg/day, although regeneration of hyaline cartilage was confirmed. Histological evaluation at 12 weeks after transplantation (i.e., 8 weeks after termination of immunosuppression) showed strong immune rejection of human chondrocytes, which indicated that, even after engraftment, articular cartilage is not particularly immune privileged in xenogeneic transplantation. Our results suggest that Japanese white rabbits administered tacrolimus at 1.6 mg/kg/day and evaluated at 4 weeks may be useful as a preclinical model for the direct evaluation of human cell-based therapies. (Brittberg et al., 2016) . OA is a debilitating disease that limits mobility and imposes a major social and healthcare burden, especially in ageing populations. The increases in longevity and size
of the elderly population mean that more people are living longer with disability and a reduced quality of life (Ondrésik et al., 2017) .
Therapies for restoring normal knee function through the regeneration of articular cartilage have been investigated (Mardones, Jofré, & Minguell, 2015) , but the development of an effective treatment for OA is still a work in progress. To date, bone marrow-stimulation techniques (Erggelet & Vavken, 2016) ; autologous and allogeneic osteochondral grafts (Bugbee, Pallante-Kichura, Görtz, Amiel, & Sah, 2016; Hangody & Füles, 2003) ; and autologous chondrocyte implantation (Brittberg et al., 1994; Clavé et al., 2016; Tohyama et al., 2009 ) have been used for the treatment of relatively small cartilage defects. The clinical outcomes so far suggest some success, but evidence is inconclusive, and there are concerns about repair with fibrocartilage and donor site morbidity (Matricali, Dereymaeker, & Luyten, 2010) .
Novel therapies being developed for articular cartilage repair can be categorized as scaffold only, cells with a scaffold, or cells without a scaffold (scaffoldless; Kon, Roffi, Filardo, Tesei, & Marcacci, 2015) . Our approach has been to use cell sheet technology developed in the 1990s (Kikuchi, Okuhara, Karikusa, Sakurai, & Okano, 1998; Okano, Yamada, Okuhara, Sakai, & Sakurai, 1995; Yamada et al., 1990) to culture chondrocytes on temperature-responsive culture inserts coated with poly(N-isopropylacrylamide), which allows the collection of chondrocytes as cell sheets without disrupting the extracellular matrix.
Using this scaffoldless technology, we have reported the usefulness of layered chondrocyte sheets (Kokubo et al., 2016) in the treatment of partial-thickness defects in rabbits (Kaneshiro et al., 2006) and full-thickness defects in rats (Takaku et al., 2014) ; rabbits (Ito et al., 2012) ; and minipigs (Ebihara et al., 2012) . In a clinical study from 2011 to 2014, we treated eight patients with autologous chondrocyte sheets and confirmed the safety and effectiveness of this method in treating patients with OA (Sato, Yamato, Hamahashi, Okano, & Mochida, 2014) .
However, autologous transplantation requires two surgeries, and the cell source is often limited. Thus, we are currently investigating the possibility of creating allogeneic chondrocyte sheets. For cartilage regeneration, both differentiated (Ham et al., 2015) and undifferentiated mesenchymal stem cells (Richardson et al., 2016) from various sources such as bone marrow, adipose tissue, and synovial tissue have been investigated as potential sources. Hyaline cartilaginous tissue generated from embryonic stem cells (Oldershaw et al., 2010) and, more recently, from induced pluripotent stem cells (Yamashita et al., 2015) shows great potential. To address the feasibility and traceability issues, we have been investigating the use of chondrocytes obtained from young polydactyly patients (Nasu, Takayama, & Umezawa, 2016) in preparation for a first-in-human clinical study for allogeneic chondrocyte sheets that has been approved by the Ministry of Health, Labour and Welfare of Japan.
The main objective of this study was to establish a preclinical animal model that would allow the direct evaluation of human chondrocyte sheets for translational research purposes. Rabbits are phylogenetically and anatomically more closely related to humans than rodents (Schnupf & Sansonetti, 2012) , and the size of defects that can be created allows for the transplantation of a single chondrocyte sheet without overpopulating the defect. Human adult chondrocyte sheets were fabricated from surgical remains of total knee arthroplasty (TKA) and transplanted into osteochondral defects in Japanese white (JW) rabbits immunosuppressed by tacrolimus, a potent immunosuppressant used in organ transplantation (Ikebe et al., 1996; Kino et al., 1987) . We hypothesized that a xenogeneic transplantation rabbit model would be a cost-effective method for the direct evaluation of the in vivo efficacy of human chondrocyte sheets.
| MATERIALS AND METHODS
The animal experiments were approved by the Institutional Animal 
| Fabrication and analysis of TKA sheets
Under the approval and guidance of the Tokai University Ethics Committee and with patients' informed consent, cartilage and synovial tissues were obtained from five patients (age 61-80 years; average age 71.4 years) who underwent TKA at Tokai University Hospital.
Chondrocytes and synovial cells were enzymatically isolated, and chondrocyte sheets made from cells obtained from TKA (TKA sheets) were prepared separately from each donor using the coculture method as previously described (Kokubo et al., 2016) . Briefly, cartilage tissue and synovial tissue were separately minced and digested with 5 mg/ml collagenase Type I (Worthington Biochemical Corp., Lakewood, NJ, USA) in Dulbecco's modified Eagle's medium-Nutrient Mixture F-12 (DMEM/F12; Gibco, Waltham, MA, USA) supplemented with 20% fetal bovine serum (FBS; Ausgenex, Molendinar, Australia) and 1% antibiotic-antimycotic solution (AA; Gibco). The cells were filtered through a 100-μm cell strainer (Becton, Dickinson, and Company [BD] , Franklin Lakes, NJ, USA) and washed in phosphate-buffered saline (PBS; Gibco). Primary chondrocytes were stored at −80°C in Cellbanker 1 cryopreservation medium (Zenoaq, Fukushima, Japan), and synovial cells were cultured to Passage 1 and then stored similarly.
To fabricate TKA sheets, synovial cells at Passage 1 were first plated as feeder cells in six-well dishes (BD) at a density of 1 × 10 4 cells per cm 2 with 3 ml of medium. After 1 hr, temperature-responsive culture inserts (Cellseed, Tokyo, Japan) were placed in the wells, and primary chondrocytes were seeded without direct contact to synovial cells at a density of 5 × 10 4 cells per cm 2 with 2 ml of medium. The medium was changed every 3 or 4 days thereafter with the addition of 100 μg/ml ascorbic acid (Wako Pure Chemical Industries, Osaka, Japan). At 2 weeks, three sheets of only chondrocytes were layered using a support membrane of polyvinylidene difluoride, and the layered sheets were cultured for another 7 days.
To count the cells, fabricated TKA sheets were digested enzymatically and stained with trypan blue. For histological analysis, TKA sheets were fixed in 4% paraformaldehyde in phosphate buffer and embedded in optimal cutting temperature compound (Sakura Finetek Japan, Tokyo, Japan 
| Measurement of blood tacrolimus concentration in JW rabbits
All JW rabbits were purchased from Tokyo Laboratory Animals Science Co. (Tokyo, Japan). The blood concentration of tacrolimus was monitored in three female JW rabbits (average weight = 3.0 kg) independent from the transplantation experiment. Tacrolimus (Astellas Pharma, Tokyo, Japan) was administered daily for 14 days intramuscularly at a dosage of 1.6 mg/kg/day. Blood samples from the ear were collected into EDTA 2 K tubes (Tokuyama Sekisui Co., Yamaguchi, Japan); frozen at −30°C; and sent to SRL Inc. (Tokyo, Japan) for analysis. Tacrolimus concentration in blood was measured using an electrochemiluminescence immunoassay on a Cobas e 411 immunoassay analyser (Hitachi High Technologies Co., Tokyo, Japan) with a minimum detection level of 0.5 ng/ml.
| Transplantation of TKA sheets
Thirty female JW rabbits (average weight = 3.0 kg) were used in the transplantation experiment. The animals were housed one animal per cage and were given daily standard chow and access to water ad libitum. Before surgery, rabbits were randomly assigned by weight to one of five groups: A (defect only, 4 weeks, 1.6 mg/kg/day of tacrolimus); B (TKA sheet, 4 weeks, 0.8 mg/kg/day); C (TKA sheet, 4 weeks, 1.6 mg/kg/day); D (defect only, 12 weeks, 1.6 mg/kg/day); and E (TKA sheet, 12 weeks, 1.6 mg/kg/day). TKA sheets fabricated from each of the donors were equally allocated to each transplantation group.
Tacrolimus was administered intramuscularly daily for 10 days starting 2 days before transplantation and then every other day until 4 weeks after surgery. The intramuscular injections alternated between the right and left hind legs.
For surgery and transplantation, the rabbits were anaesthetized with 2 L/min nitrous oxide, 1 L/min oxygen, and 2.5-3.0% isoflurane (Pfizer, New York City, NY, USA). A medial parapatellar incision was made to the right knee, and the patella was dislocated to access the patellar groove of the femur. A 5-mm biopsy punch (Kai Industries, Gifu, Japan) was used as a marking guide, and a 5-mm drill was used to create an osteochondral defect (diameter = 5 mm; depth = 3 mm). Slight bleeding from the subchondral bone was confirmed, and physiological saline (Nipro, Osaka, Japan) was used to clean the defect and prevent thermal damage. For transplantation groups B, C, and E, one TKA sheet was transplanted into each defect without suturing. After restoration of the patella, the quadriceps femoris muscle and tendon were sutured to prevent dislocation. 
| Monitoring of biochemical markers in blood

| Pain evaluation
The Linton Incapacitance Tester (Linton Instrumentation, Diss, Norfolk, England) was used to evaluate the degree of pain, inflammation, or discomfort, as previously reported (Ito et al., 2012) . Measurements were made before surgery, on Days 1, 4, 7, 10, 14, 17, 21, 24, and 28 for the first 4 weeks, and on Days 35, 42, 49, 56, 70 , and 84 for the following 8 weeks. The average damaged limb weight distribution ratio (%) of the hind limbs was calculated from 10 repeated measurements for each animal and averaged for all groups as follows.
Damaged limb weight distribution ratio
2.6 | Histological evaluation of regenerated cartilage
Rabbits were euthanized by an intravenous administration of 50 mg/ ml pentobarbital (Tokyo Chemical Industry, Tokyo, Japan) at 4 weeks or 12 weeks. The operated knee was opened, and the distal portion of the femur was excised and fixed in 20% formalin (Wako Pure
Chemical Industries) for 3-5 days. The sample was decalcified in 10% EDTA (Wako Pure Chemical Industries) for 3-4 weeks and embedded in paraffin wax, and 3-μm sections were cut near the centre of the defect area, parallel to the long axis of the femur.
Standard protocols were used for histological staining. All microscopic images were obtained using a BZ-9000 Generation II fluorescence microscope (Keyence Corp.).
| Statistical analysis
Numerical results are expressed as mean and standard deviation unless otherwise noted. ICRS scores are expressed as mean and standard error of the mean. Repeated measures analysis of variance was used to analyse measurements from the monitoring of biochemical makers in blood. Analysis of variance was used to analyse ICRS scores, and Tukey's honest significance test was used for post hoc analysis. The weight distribution ratios were compared with values before surgery using the paired t test.
3 | RESULTS
| Properties of TKA sheets
An average TKA sheet contained 1.6 ± 0.2 × 10 6 cells and had a thickness of 50.0 ± 6.5 μm. The sheets were layered and manipulated using a polyvinylidene difluoride support membrane, which was removed upon transplantation (Figure 1a,b) . HE staining of TKA sheets showed the integration of the three chondrocyte sheet layers and the multilayer of chondrocytes 1 week after layering (Figure 1c ). TKA sheets stained negative for Safranin O (Figure 1d ), positive for COL1 (Figure 1e ), slightly positive for COL2 (Figure 1f ), positive for aggrecan (Figure 1g ), and positive for fibronectin (Figure 1h ). Enzyme-linked immunoassays showed that an average TKA sheet produced 1.8 ± 0.2 ng/ml of transforming growth factor-β1 and 14.3 ± 2.1 ng/ ml of MIA in 3 ml of culture media in 72 hr.
| Blood tacrolimus concentration in JW rabbits
The blood tacrolimus concentration (ng/ml) in three JW rabbits admin- Day 4. Adverse events were detected near the end of the 4 weeks in two rabbits from Group C and in four rabbits from Group B. Selfinflicted wounds to the end of the hind limbs were observed, but no abnormalities to the surgical areas were detected. Adverse events were detected in two rabbits from Group E. Self-inflicted wounds to the end of the hind limbs were observed in one rabbit, and swelling in the surgical knee joint was detected in the other. In all rabbits, muscle stiffness and muscle loss were observed in areas where tacrolimus had been administered.
| Monitoring of biochemical markers in blood
Blood monitoring was performed weekly for selected rabbits (n = 3) in defect group A and transplantation group C (Table 1) 
| Pain evaluation
The weight distribution ratio was used as a measure of pain and was followed for 4 weeks ( Figure 3a ) and 12 weeks (Figure 3b ). This ratio recovered to the value before surgery by Day 21 in transplantation groups B (p = 0.972) and C (p = 0.214) but did not return fully to the 
| DISCUSSION
Hyaline cartilage regeneration using chondrocyte sheets may provide an effective and long-term treatment for OA. To ensure the safety and efficacy of this treatment using different cell sources, preclinical models are needed for evaluating human chondrocyte sheets directly.
Such models will also be critical for evaluating differences associated with donor age, gender, health status, and other factors yet to be identified. In this study, we have shown the usefulness of a rabbit xenogeneic transplantation model for the direct evaluation of human chondrocyte sheets.
JW rabbits were immunosuppressed by tacrolimus at two different concentrations, 0.8 and 1.6 mg/kg/day, and human TKA sheets were transplanted into osteochondral defects. We verified that TKA sheets expressed fibronectin important to the adhesive properties of chondrocyte sheets and that they also produced TGFβ-1 and MIA, which are known anabolic factors that may contribute to the regenerative effects. At 4 weeks and under immunosuppression of 1.6 mg/kg/ day, successful engraftment of human chondrocytes, pain alleviation, and improvement in histological scores were observed. To our knowledge, this is the first study to provide clear evidence of the successful engraftment of human chondrocytes in the injured rabbit knee and to characterize the cartilage matrix produced by the transplanted chondrocytes. Immunostaining indicated repair by both hyaline cartilage and fibrocartilage, which may be indicative of the advanced age and OA nature of the adult chondrocytes used in this study. Muscle stiffness and muscle atrophy at the sites of tacrolimus injections were observed on both hind legs, but the results of the weight distribution ratios were comparable with those reported in our previous study (Ito et al., 2012) . humoral factors produced by chondrocyte sheets, as we reported previously (Hamahashi et al., 2015) . The paracrine effect was also reported to be the major mode of action of cell sheet treatment of ischaemic cardiomyopathy in a porcine xenogeneic transplantation model (Kawamura et al., 2012; Kawamura et al., 2015) . The rejection of transplanted cells may occur in parallel with the paracrine effect and may result in regeneration of hyaline cartilage by activated host cells even when no donor cells remain.
We also examined whether this model could be used to evaluate the remodelling of articular cartilage over the long term. We hypothesized that, after successful engraftment and matrix production, immunosuppression may be unnecessary. However, histological evaluation at 12 weeks after transplantation (i.e., 8 weeks after termination of immunosuppression) showed that immune rejection had occurred.
The articular cartilage has long been considered a relatively immune- A key limitation of our study is that tacrolimus has been shown to reduce OA-like responses and to protect cartilage matrix integrity in vitro and in vivo (Siebelt et al., 2014) . These effects may complicate the interpretation of our results. Intramuscular administration of tacrolimus alone was insufficient for allowing the regeneration of articular cartilage in this rabbit model. However, tacrolimus may stimulate or modify the cartilage-regenerating effect resulting from the transplantation of chondrocyte sheets. Further studies are needed to determine the extent to which transplanted cells may be affected.
Another limitation is that tacrolimus administration was accompanied by adverse events such as weight loss and self-inflicted wounds.
Self-inflicted wounds and muscle loss increased the variability in the weight distribution ratio. Blood monitoring did not indicate kidney or liver failure, but these adverse events limited tacrolimus administration to 4 weeks in this study and would limit its use in longer studies. Differences in tacrolimus toxicity between rabbit species must also be considered in order to translate our results to other rabbit species. Severe tacrolimus toxicity was reported in the DutchBelted rabbit, and a much lower dosage of 0.08 mg/kg/day has been suggested as feasible (Giessler, Gades, Friedrich, & Bishop, 2007) .
JW rabbits can tolerate 1.6 mg/kg/day, as first described by Ikebe et al. (1996) in bone xenogeneic transplantation, but the optimal concentrations need to be determined in further studies.
Chondrocyte sheets are unique in that the transplanted chondrocytes may survive over the long term in the recipient in addition to contributing to the regeneration of cartilage through a paracrine effect. Few clinical studies have tracked the fate of donor chondrocytes in humans. In several studies with fresh osteochondral allografts, donor chondrocytes were reported to be alive and active in the patients after 29 years (Jamali, Hatcher, & You, 2007) . 
